An experimental optogenetic therapy partly restored sight in some blind patients, a New England Journal of Medicine study shows.

The PIONEER trial enrolled 10 people with advanced retinitis pigmentosa and profound vision loss.

Six of the 10 participants gained clinically meaningful improvements in their light sensitivity.

Each patient got one gene injection in the worse eye, delivering a light-sensitive protein called ChrimsonR.

Special goggles turn brightness changes into amber light patterns projected onto the retina.

Wearers can perceive a monochrome image of their surroundings, though vision remains partial.

The results came two days after optogenetics won the 2026 Nobel medicine prize.

Read the full article for more details on the optogenetic vision therapy trial.